Cardiac contractility modulation (CCM) is a novel, approved, implantable therapy that significantly improves heart failure symptoms, exercise tolerance, and quality of life while reducing the rate of heart failure hospitalizations. Find out why you should consider sending your patients with NYHA Class III heart failure who are not responding to guideline-directed medical therapy directly to an electrophysiologist for device implantation.
What can you do when GDMT isn’t working? Learn about CCM, an implantable device-based therapy that’s improving symptoms and QoL in patients with HF.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Javed Butler, MD, MBA, MPH
President, Baylor Scott and White Research Institute
Distinguished Professor of Medicine, University of Mississippi Medical Center
Consulting Fees: Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceuticals, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, V-Wave Ltd., Vifor Pharma
William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE
Professor of Medicine, Physiology, and Cell Biology
College of Medicine Distinguished Professor
Division of Cardiovascular Medicine
The Ohio State University
Consulting Fees: Boehringer Ingelheim, Cardionomic, Impulse Dynamic, Respicardia, Inc., Tegosens, Inc., Vectorious
- Cindy Davidson has nothing to disclose.
- Howard Green has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- Jay Runyon has nothing to disclose.
- Katie Sheridan, PhD, has nothing to disclose.
- Mario Trucillo, PhD, MS, has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Discuss heart failure-related morbidity and mortality outcomes despite the use of guideline-directed medical therapy (GDMT)
- Review the latest clinical data on the use of cardiac contractility modulation (CCM) therapy in patients with heart failure
- Select patients with heart failure who would benefit from CCM therapy and refer them directly to an EP
This activity is designed to meet the educational needs of cardiologists.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
This activity is supported by an independent educational grant from Impulse Dynamics, Inc.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Case-Based Management of Hyperkalemia to Optimize RAASi Therapy in Patients with CKD0.25 credits
Mikhail Kosiborod, MD
Biff F. Palmer, MD
Kieran McCafferty, MD
Prof. Dr. Jörg Latus
Hemal Gada, MD
Renuka Jain, MD
Steven Yakubov, MD, MSCAI, FACC